Hundreds of thousands of undocumented therapies occur in clinics world-wide each year under the label of ‘medical tourism’. Even if physicians in these clinics wanted to follow their patients, there has been no method of doing so. Until now. Regenetek Research recognizes that there is a high need for a method and a study design that provides proof of both safety and efficacy for new treatment interventions such as autologous stem cell therapies or unsanctioned vascular surgeries. These types of medical interventions present viable choices for patients beyond conventional drug therapies that only treat symptoms. My goal in writing these articles is to point out the gaps in the research while we look for the truth, not reinforce the biases in the science.
To provide some background here for David Echt’s post, 6 months after treatment in March of 2014, David wasn’t experiencing the recovery we are seeing in other patient/subjects over the same time period, post-therapy. Although there were some important improvements, there was no functional difference in his affected right leg whatsoever; it was still as paralyzed as it had been for the past 6 years. This didn’t make a lot of sense to us. We knew he was on Metformin for his diabetes, but as far as we knew, that shouldn’t have interfered with the activity of the stem cells…OR SO WE THOUGHT. Then we came across a new article entitled ‘The paradoxical effect of metformin on endothelial cells and angiogenesis’. The research concluded that the drug Metformin would have precisely the OPPOSITE effect of what would be expected. Instead of fostering stem cell activity and endothelial growth, it INHIBITED these growth activities, which was a stunning surprise to the researchers. Metformin would therefore inhibit the formation of capillary networks, negate the trophic effect of stem cells in the brain, and likely disrupt endothelial, myelin and neuronal growth. So despite what we THOUGHT WE KNEW, many drug interactions with stem cells are difficult to make recommendations about these drugs because there has not been enough work done in this area of study. It really requires a deep dive into medical journals. What we are witnessing with David’s dramatic demonstration is real medical pioneering stuff. And now we know a couple more things. Because David’s recovery has now resumed, we have a good demonstration of the lasting effect of the ‘type’ of stem cells (mesenchymal neural progenitor cells or ‘true stem cells’) we’re typing, isolating, and colonizing for reinfusion.